A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors

Desmoid fibromatosis (DF) are mesenchymal neoplasms, with potential aggressive course and relevant clinical impact. New systemic therapy modalities are needed in this symptomatic/progressive population. In this multicenter, phase II trial (NCT03275818), patients with symptomatic/progressing DF recei...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin-Broto, Javier, Redondo, Andres, Moura, David S., Valverde, Claudia, Morales, Jose Manuel, Lopez-Pousa, Antonio, Martinez-Trufero, Javier, Gutierrez, Antonio, Díaz-Beveridge, Roberto, Luna, Pablo, Martinez-Marin, Virginia, Marcilla, David, Arribas, Ivan, Ledesma, Patricio, Lopez-Martin, Jose Antonio, Di Lernia, Davide, Zamora, Jorge, Hindi, Nadia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587294/
https://www.ncbi.nlm.nih.gov/pubmed/36271011
http://dx.doi.org/10.1038/s41467-022-33975-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587294/
https://www.ncbi.nlm.nih.gov/pubmed/36271011
http://dx.doi.org/10.1038/s41467-022-33975-6

Ejemplares similares